Sibrafiban
| Code | Size | Price |
|---|
| TAR-T28775-50mg | 50mg | £1,091.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28775-100mg | 100mg | £1,669.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-prodrug of Ro 44-3888 which is a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation [1] [2] [3].
CAS:
172927-65-0
Molecular Weight:
420.46
Purity:
0.98
SMILES:
CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)c1ccc(cc1)C(\N)=N\O
References
Wong CK, Newby LK, Bhapker MV, Aylward PE, Pfisterer M, Alexander KP, Armstrong PW, Hochman JS, Van de Werf F, Califf RM, White HD; SYMPHONY and 2nd SYMPHONY Investigators.. Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. Am Heart J. 2007 Aug;154(2):313-21. PubMed PMID: 17643582.
Second SYMPHONY Investigators.. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation. 2001 Apr 3;103(13):1727-33. PubMed PMID: 11282902.
Feldstein CA. Sibrafiban (Genentech). IDrugs. 1999 May;2(5):460-5. PubMed PMID: 16155849.
Frazier CG, Shah SH, Armstrong PW, Bhapkar MV, McGuire DK, Sadowski Z, Kristinsson A, Aylward PE, Klein WW, Weaver WD, Newby LK; SYMPHONY and the Second SYMPHONY Investigators.. Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. Am Heart J. 2005 Dec;150(6):1260-7. PubMed PMID: 16338269.